0.5248
전일 마감가:
$0.55
열려 있는:
$0.543
하루 거래량:
75,097
Relative Volume:
0.11
시가총액:
$32.42M
수익:
-
순이익/손실:
$-68.80M
주가수익비율:
-0.4485
EPS:
-1.17
순현금흐름:
$-59.06M
1주 성능:
-6.29%
1개월 성능:
-14.94%
6개월 성능:
-29.72%
1년 성능:
-57.68%
Passage Bio Inc Stock (PASG) Company Profile
명칭
Passage Bio Inc
전화
(267) 866-0312
주소
ONE COMMERCE SQUARE, PHILADELPHIA, PA
PASG을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PASG
Passage Bio Inc
|
0.5248 | 32.42M | 0 | -68.80M | -59.06M | -1.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-11-29 | 재개 | Wedbush | Outperform |
2024-09-03 | 개시 | Rodman & Renshaw | Buy |
2022-03-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2022-01-19 | 다운그레이드 | Goldman | Buy → Neutral |
2021-07-01 | 개시 | Raymond James | Outperform |
2021-06-15 | 개시 | BTIG Research | Buy |
2021-03-04 | 업그레이드 | Goldman | Neutral → Buy |
2021-02-04 | 개시 | Guggenheim | Buy |
2021-01-25 | 개시 | Wedbush | Outperform |
2021-01-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
2020-12-11 | 개시 | Citigroup | Neutral |
2020-08-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-06-25 | 다운그레이드 | Goldman | Buy → Neutral |
2020-03-25 | 개시 | Chardan Capital Markets | Buy |
2020-03-24 | 개시 | Cowen | Outperform |
2020-03-24 | 개시 | Goldman | Buy |
2020-03-24 | 개시 | JP Morgan | Overweight |
모두보기
Passage Bio Inc 주식(PASG)의 최신 뉴스
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
Passage Bio Inc to Host Earnings Call - ACCESS Newswire
Passage Bio (NASDAQ:PASG) versus SpringWorks Therapeutics (NASDAQ:SWTX) Head to Head Review - Defense World
Passage Bio will again trim workforce in latest cost-cutting move - The Business Journals
Passage Bio CFO sells shares worth $1,685 - MSN
Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech
Passage Bio CFO sells shares worth $1,685 By Investing.com - Investing.com UK
2024 Q4 Job Market Report: Biopharma Job Postings Slowed as Layoffs Continued - BioSpace
Passage Bio shares transition to Nasdaq Capital Market - MSN
Passage Bio shares transition to Nasdaq Capital Market By Investing.com - Investing.com South Africa
TELA Bio Grants Inducement Stock Units to New Employees - MyChesCo
Passage Bio Out-Licenses Rare Disease Programs to GEMMA Biotherapeutics - MSN
Annovis Bio Secures U.S. Patent for Neuroprotective Drug Buntanetap - MyChesCo
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
Orbimed advisors reduces stake in Passage Bio for $142,223 By Investing.com - Investing.com South Africa
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MSN
Orbimed advisors reduces stake in Passage Bio for $142,223 - Investing.com
Gryphon Bio, Inc. Pioneers Novel Blood Biomarker Panel to Monitor Treatment Journey for Patients with Traumatic Brain Injury and Alzheimer's - BioSpace
Passage Bio Cutting 55% of Staff to Help Extend Cash Runway - BioSpace
Geode Capital Management LLC Has $351,000 Position in Nutriband Inc. (NASDAQ:NTRB) - Defense World
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Geode Capital Management LLC - Defense World
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
Head-To-Head Comparison: Passage Bio (NASDAQ:PASG) vs. JATT Acquisition (NYSE:JATT) - Defense World
Passage Bio Inc (PASG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):